There exist in NATURE a number of microscopic organisms that exhibit survival traits under extreme conditions. Several exhibit survival traits under extensive
radiation fields. One such
organism is
Deinococcus Radiodurans. (refer to Refs 1 a and 1 b of PRIOR ART) We believe that this survival trait is genetically based. We claim that this genetic trait can be utilized for enhancement of
radiation susceptibility and resistance and can be encapsulated in a pharmaceutical. This is partially confirmed in Ref 1c for a
human cell system (refer to the PRIOR ART section), and justifies our Patent. We claim as our invention a pharmaceutical selectively utilizing the
Deinococcus Radiodurans genes, and
DNA /
RNA genetic as well as chemical repair
system, for the application to
radiation treatment of human
Glioblastoma Brain Cancer. We claim that we can utilize this pharmaceutical for the targeted enhancement of radiation susceptibility and resistance in the cancerous and healthy tissues, using energetic Protons or Carbon lons and the associated
Bragg Peak selected energy deposition for these regions. We claim that this pharmaceutical can also be utilized with other focused radiation modalities such as X-Rays or
electron beams, but not as effectively. We specifically select the DR1709
Deinococcus Radiodurans
gene for this application and the DrRRA(DR2418)
Deinococcus Radiodurans gene for this application. We do not exclude other
Deinococcus Radiodurans genes, and
DNA /
RNA genetic as well as chemical repair systems not known at this time to this inventor currently or in the future. We do not exclude genes of other micro-organisms that survive under extreme conditions. However, only the application of
radiation resistant micro-
organism genetic material to create a pharmaceutical for the control of
radiation resistance and susceptibility is being patented with a specific
organism and
gene set as the basis of this Patent (i.e.,
Deinococcus Radiodurans) and the application to the radiation treatment of human
Glioblastoma Brain Cancer.